BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 17961866)

  • 1. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract]   [Full Text] [Related]  

  • 2. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D; Humbert M; Hachulla E
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil in the treatment of pulmonary hypertension.
    Barnett CF; Machado RF
    Vasc Health Risk Manag; 2006; 2(4):411-22. PubMed ID: 17323595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
    Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R
    Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil for enhanced performance at high altitude?
    Rubin LJ; Naeije R
    Ann Intern Med; 2004 Aug; 141(3):233-5. PubMed ID: 15289224
    [No Abstract]   [Full Text] [Related]  

  • 9. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summaries for patients. Sildenafil increases exercise capacity in low-oxygen settings.
    Ann Intern Med; 2004 Aug; 141(3):I12. PubMed ID: 15289233
    [No Abstract]   [Full Text] [Related]  

  • 11. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Kuschner WG
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528810
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
    Watanabe H
    Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil for pulmonary hypertension in ARDS: a new pleasant effect?
    Blanch L; Albaiceta GM
    Intensive Care Med; 2010 May; 36(5):729-31. PubMed ID: 20130829
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 16. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Izbicki G; Rosengarten D; Picard E
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
    [No Abstract]   [Full Text] [Related]  

  • 17. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
    Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
    Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].
    Kayikçioğlu M; Can LH; Payzin S; Kültürsay H; Soydan I
    Anadolu Kardiyol Derg; 2002 Sep; 2(3):262-4. PubMed ID: 12223337
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
    Minai OA; Arroliga AC
    South Med J; 2006 Aug; 99(8):880-3. PubMed ID: 16929886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.